Trump Administration Plans Temporary Sale of 7 Restricted Peptides as FDA Weighs New Rules
Updated
Updated · The Washington Post · Oct 8
Trump Administration Plans Temporary Sale of 7 Restricted Peptides as FDA Weighs New Rules
1 articles · Updated · The Washington Post · Oct 8
Summary
Certain previously restricted peptides could be temporarily sold through compounding pharmacies under a Trump administration plan that has not been announced and could still change.
Seven peptide treatments for conditions including obesity, insomnia and wound healing are under FDA review, even though career scientists said in late June the evidence was too weak to support compounding them.
Robert F. Kennedy Jr., a self-described peptide fan, has pushed broader access, while officials discuss guardrails such as patient disclosures, adverse-event reporting and data collection.
FDA scientists and outside experts warn many wellness peptides lack rigorous clinical testing, and regulators have struggled to police gray and black markets tied to potentially tainted products.
Industry advocates and a peptide trade group argue temporary enforcement discretion would shift demand into regulated pharmacies, with one polling memo saying expanded access carries political upside.